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Abstract [ 
A semiautomated method for the determination of five frequently 
prescribed benzodiazepines (BZD) (clonazepam, diazepam, 
flunitrazepam, midazolam, and oxazepam) in whole blood samples 
by reversed-phase high-performance liquid chromatography 
following simple online enrichment and clean-up on a short 
precolumn is described. After precipitation of protein and red cells 
with a mixture of organic solvents (methanol/acetonitrile, 50:50), 
the aliquot is centrifuged and the organic upper phase evaporated 
under a gentle stream of nitrogen. The residue is reconstituted by 
adding 500 pL of a mixture of phosphate buffer (20raM, pH 2.2) 
and acetonitrile (70:30, v/v). The sample is then directly introduced 
into the column-switching column. The precolumn is first washed 
with phosphate buffer at pH 7.2. Compounds retained on the 
precolumn are then eluted in the back-flush mode and separated 
on a C 8 semi-microcolumn (tichrospher select B, 125 x 3 mm). The 
BZD studied are determined by a diode-array detector at 254 nm. 
The method shows excellent linearity between 25 a d 1000 ng/mL 
for clonazepam, flunitrazepam, and midazolam and between 25 
and 5000 ng/mt for diazepam and oxazepam. The recoveries are 
around 80% for clonazepam and oxazepam and around 90% for 
the three others. Coefficients of variation for between-day and 
within-day assays are < 15% for low concentrations close to the 
limit of quantitation and < 5% for high concentrations. 
Introduction 
have been frequently reported (5-9). Furtherstudies have been 
carried out (10-12), and comparisons have been made between 
GC-MS techniques and various immunoassays (13,14). 
High-performance liquid chromatography methods (HPLC) 
are often applicable to only one drug and its metabolites 
(15-17). Furthermore, papers reporting screening procedures 
(18) do not specifically address the problem of clinical and tox- 
icological screening, as very often two or more unrelated drugs 
are co-administered with benzodiazepines. 
The chromatographic theory and method development b - 
hind column-switching or online preconcentration techniques 
have been reviewed and described (19-21). 
This paper describes a column-switching technique in wh ch 
whole blood samples are injected, after protein and red cell 
precipitation with a mixture of organic solvent, into a BioTrap 
500 MS column (extraction column) a d are then washed with 
a mixture of 30raM phosphate buffer (pH7.2) and acetonitrile 
mobile phase (94:6, v/v). The drugs retained are th n eluted 
onto a C8 reversed-phase analytical column for determination. 
The method presented is rapid and easily automated and al- 
lows to determine BZD regularly encountered in clinical a d 
toxicological cases. The column-switching technique offers 
several advantages: direct injection of biological fluids, non- 
manual or robotic clean-up, semiautomated and minimized 
contact with e infectious biological fluids, on-column en- 
richment of analytes, and low cost per sample. 
Benzodiazepines (BZD) are often used as antianxiety agents 
in the treatment of psychiatric disorders (1--4). Various re- 
searchers have reported total plasma BZD concentration related 
to both clinical effect and toxicity. Avariety of methods for the 
detection and determination of BZD in biological matrices are 
described inthe literature. 
Gas chromatography-mass spectrometry (GC-MS) methods 
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Experimental 
Chemicals 
Clonazepam, diazepam, flunitrazepam, midazolam, and ox- 
azepam were purchased from Promochem (Molsheim, France). 
Human plasma was obtained from the University Hospital of 
Geneva (Switzerland). 
Monobasic and dibasic potassium phosphate and phosphoric 
acid were purchased from Merck (Darmstadt, Germany), and 
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HPLC-grade acetonitrile was obtained from Romil (Cambridge, 
England). 
Stationary and mobile phases 
The column-switching procedure was achieved by using a 
BioTrap 500 MS (Chromtec, Hiigersten, Sweden), a new bio- 
compatible extraction column offering repeated direct injection 
of serum, plasma, supernatant of cell culture, or other complex 
matrices, into the HPLC system without any clean-up proce- 
dure (except a simple centrifugation). This biocompatible ex- 
traction column is pH stable (between pH 2 and pH 11) with a 
biocompatible external surface (cd-acid glycoprotein) and a 
hydrophobic internal surface (hydrophobic polymer). 
The surface within the pores is also a hydrophobic polymer, 
and the matrix pores are small enough to exclude plasma pro- 
Table I. Optimized Conditions 
Component Description 
Extraction column 
Analytical column 
Loading 
Transfer and analytical 
separation 
Detection 
Volume of plasma 
injected 
Biotrap MS 500 20 x 4.0-mm i.d 
Thermostated at 35~ 
Lichrospher select-B 125 x 3-mm i.d, 5pm 
Thermostated at 35~ 
K2HPO4, (30mM, pH 7.2) 
5 min at 0.6 mL/min 
A = Acetonitrile (ACN), 
B = KH2PO 4, (20raM, ph 2.1) 
Linear gradient 
0 rain: A/B 30:70 at 0.5 mL/min 
30 min: A/B 35:65 at 0.3 mL/min 
254 nm 
50pL 
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tein and other macromolecular compounds. 
The separation was performed using a C8 reversed-phase 
semi-microcolumn (LiChrospher Select B, 125 x 3-mm i.d., 
5-1am particle size) and a guard column (Nucleosil NH2 8 x 4- 
mm i.d., 5-1am particle size, Macherey-Nagel, Oensingen, 
Switzerland). This method was recently validated (22). 
The column switching mobile phase consisted of 30mM phos- 
phate buffer (pH 7.2) and acetonitrile (94:6, v/v). The analytical 
mobile phase comprised a mixture of 20raM phosphate buffer 
(pH 2.1) and acetonitrile. The optimized conditions of this 
technique are detailed in Table I. 
Column-switching system 
A representative column-switching technique set-up is given 
in Figure 1. The online system consisted of two quaternary 
pumps (model HP 1100) and two columns connected by an HP 
1100 high-pressure six-port valve in back-flush configuration. 
The chromatographic system was equipped with a diode-array 
detector, an automatic injector, and an autosampler. 
In extraction position, pump A pumped the extraction mobile 
phase through the autosampler, into which the sample was in- 
jected. A filterholder was inserted after the autosampler with a 
2-1am biocompatibility filter. After passing through the filter, the 
sample was transported to the extraction column via the six- 
port valve. During this time, analytical pump B pumped the an- 
alytical mobile phase through the column via the six-port valve. 
In elution position, the mobile phase from pump A (the ex- 
traction mobile phase) went o waste. The mobile phase from 
pump B (analytical mobile phase) back-flushed from t  ex- 
traction column to the analytical column. 
The strong elution power of the second mobile phase deliv- 
ered by pump B caused analyte desorption from the extraction 
column. The change in flow direction (back-flush) caused ad- 
ditional analyte concentration. 
Extraction position and separation position 
(original position) 
Pump I
Pump 2 
" '~"  ~ ~  ^~ Rotation 60" 
Figure 1. Schematic representation of the column-switching set-up. Adapted from reference 23. 
Transfer position 
Pump 1 
Pump 2 
w~ 
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Figure 2. Chromatogram of drug-free blood sample (top). Chromatogram 
of spiked blood with clonazepam (300 ng/mL), flunitrazepam (300 
ng/mL), midazolam (300 ng/ml_), diazepam (I 000 ng/mL), and oxazepam 
(1000 ng/mL)(bottom), and methyIclonazepam (2000 ng/ml I.S.). Ex- 
traction conditions: injection, 50 ml. of b ood sample (after precipitation) 
on BioTrap 500 MS extraction (20 x 4-mm i.d); mobile phase, acetoni- 
trile/phosphate buffer (pH 7.2, 0.3M). Analytical conditions: C8 reversed- 
phase column, Lichrospher Select B (I 25 x 3-mm i.d); mobile phase, 
acetonitrile/phosphate buffer (pH 2.1,0.2M) (35:65, v/v) at a flow rate of 
0.3 mL/min UV detection at 254 nm. 
Table II. Calibration Data for the Five Benzodiazepines 
(n = 3) 
Range Coefficient of Line 
(pg/mL) correlation r Y = ax + b 
Clonazepam 0.025-1.0 0.995 0.0013x- 0.074 
Diazepam 0.025-5.0 0.999 0.002x + 0.048 
Flunitrazepam 0.025-1.0 0.996 0.0028x- 0.14 
Midazolam 0.025-I .0 0.997 0.0017x + 0.18 
Oxazepam 0.025-5.0 0.995 0.0015x- 0.34 
In separation position, thevalve was switched back to its 
original position (extraction position), the analyte fraction 
caused transfer into the analytical column, and analyte sepa- 
ration then took place in a conventional manner. 
Eluent absorbance was monitored at 254 nm. HP Chem- 
Station (Hewlett-Packard Software no. G2170AA) was used for 
instrument control, data acquisition, and data handling. 
Standard solutions 
Stock standard solutions of clonazepam, diazepam, fluni- 
trazepam, midazolam, ndoxazepam were prepared by dis- 
solution of each compound in methanol to obtain a concen- 
tration of I mg/mL. Stock solutions were stored at-20~ and 
remained stable for at least 24 months. 
Biological standards were prepared at th  required concen- 
trations by diluting the appropriate aliquots of he stock solu- 
tions with clean drug-free blood between 25 and 5000 ng/mL for 
both oxazepam and diazepam and between 25 and 1000 ng/mL 
for clonazepam, flunitrazepam, and midazolam (Figure 2).
Phosphate buffer 
The extraction phosphate buffer (pH 7.5, 30mM) was pre- 
pared by transferring 2.7 mL of 1M KH2PO4 and 9.9 mL of 1M 
K2HPO4 into a 1000-mL volumetric flask and making up to 
volume with distilled water. The analytical phosphate buffer (pH 
2.1, 20mM) was prepared by transferring 12.7 mL of 1M 
KH2PO4 and 22.3 mL of 1M H3PO 4 into a 1000-mL volumetric 
flask and making up to volume with distilled water. Buffer so- 
lutions were always freshly prepared and filtered through a
0.45-1Jm filter (Supelco, Bellefonte, PA) immediately before 
use. 
Sample preparation 
Whole blood samples (1 mL) were spiked with the different 
mentioned benzodiazepines at the desired concentrations and 
with 20 IJL of the appropriate internal standard (methylclon- 
azepam, 100 pg/mL). Spiked samples were mixed with 2 mL of 
a mixture of organic solvent (methanol/acetonitrile, 1:1), vortex 
mixed, and centrifuged for 10 min at 5000 rpm. The super- 
natant was evaporated to dryness and dissolved in 500 IJL of 
analytical mobile phase, th n placed into glass vials. Fifty mi- 
croliters was processed online as described. 
Table III. Repeatability and Reproducibility (n = 6) 
Clonazepam Flunitrazepam Midazolam 
Concentration repeat.* repro, repeat, repro, repeat, repro. 
(ng/mL) CV% CV% CV% CV% CV% CV% 
Oxazepam Diazepam 
repeat, repro, repeat, repro. 
CV% CV% CV% CV% 
50 15.2 14.6 12.8 13.5 13.9 9.9 
250 - - - 
300 5.2 6.7 2.4 3.5 4.9 3.4 
500 4.2 3.6 2.0 2.3 4.5 3.0 
3000 - - 
5000 - - - 
* Abbrev ia t ions :  repeat., repeatab i l i ty  and repro.,  reproduc ib i l i ty .  
~" Not  ana lyzed  at this concent ra t ion .  
t _ _ _ 
4.8 4.7 4.4 4.1 
3.8 3.1 4.0 3.7 
2.1 3.0 2.9 2.0 
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Results 
Chromatography 
The five benzodiazepines were ll separated, and the whole 
procedure allowed an extremely clean chromatographic trace 
(Figure 2). 
Linearity 
Detector response linearity was evaluated by preparing five 
triplicate calibrations covering the following concentration 
ranges: 25 to 1000 ng/mL for clonazepam, flunitrazepam, and 
midazolam and 25 to 5000 ng/mL for diazepam and oxazepam. 
Linear regression lines were obtained by plotting peak-area 
ratios (the compound peak area divided by one of the internal 
standards, see Table II). 
Mldazolam ~o CIonazepam 
5 n~mL 
IS 
+il ,+ 9 ; : : o 
o So 1oo 15o ~o ~0 ~o o 50 100 ISO ~ 2SO 3OO 
Concentration (ng/mL) Concentration (ng/mL) 
Flunltrazepam 
2O 
l \ o  ...... 
Is 
o . . . . .  __" : 
o Io I~  15o Ze  ~ ~o 
Concentration (ng/mL) 
Oxazepam 
Diazepam 
I$ 28.7 ng/mL 
15 30 ng/mL 
=< _< 
8 
0 I O,  - -  , I I ! i i i 
o 5o too ISO 2oo ~o 3Oo o 50 100 150 200 25o 
Concentration (ng/mL) Concentration (ng/mL) 
I 
300 
Figure 3. Curve determination of LOQ values. 
Table IV. Recoveries Obtained with Spiked Plasma Samples (n = 6) 
Precision 
Within-day reproducibility or repeatability (see Table III) was 
evaluated by replicate analysis (n = 6) of pooled blood at three 
different concentrations: 250, 3000, and 5000 ng/mL for di- 
azepam and oxazepam and 50, 300, and 500 ng/mL for the 
three others on the same day. The coefficients ofvariation (CV) 
obtained are shown in Table III. 
Between-day reproducibility or reproducibility (Table III) was 
determined by replicate analysis (n = 6),over three days, at the 
same concentrations as for repeatability. 
Assay detection limits 
Limit of detection (LOD). The LaD, defined as the lowest an- 
alyte concentration that can be clearly detected above the base- 
line signal, is estimated as three times the signal-to-noise ratio. 
The LaD was determined (n = 6) by injection of spiked blood 
with BZD in decreasing concentrations. LaD was determined to 
be around 15 ng/mL for clonazepam, flunitrazepam, and 
midazolam and 10 ng/mL for diazepam and oxazepam. 
Limit ofquantitation (LOQ). The LOQ (n = 6) is the lowest 
concentration that can be measured on the standard curves 
with acceptable reproducibility (CV < 15%) (Figure 3). The 
lower pratical LOQ was 50 ng/mL for clonazepam, below 40 
ng/mL for flunitrazepam and midazolam, and 30 ng/mL for 
diazepam and oxazepam. 
Recovery 
Recoveries of the five benzodiazepines studied were deter- 
mined by comparing the peak areas of the spiked blood samples 
and of the reference samples at six different concentrations. The 
reference samples were injected directly into the analytical 
column and the spiked blood samples were injected, after 
precipitation with a mixture of organic solvent, into the ex- 
traction column coupled to the analytical olumn through the 
switching valve. 
As showed in Table IV, the method gives acceptable values for 
recoveries. The observed recovery is higher than 90% for all 
BZD, except clonazepam and oxazepam (around 80%). 
Clonazepam Flunitrazepam Midazolam Oxazepam Diazepam 
Amount added mean mean mean mean mean 
(ng/mL) recovery(%) recovery(%) recovery(%) recovery(%) recovery(%) 
25 70.0 83.1 95.0 67.1 84.2 
50 67.0 88.3 101.7 -* 
100 76.7 87.0 113.0 - 
250 - 72.3 88.3 
300 76.7 84.0 100.3 - 
500 82.8 105.7 101.3 76.3 88.3 
800 81.0 97.7 107.7 - 
1000 80.0 96.0 113.3 74.3 91.0 
2000 - 74.3 104.0 
3000 - 79.3 103.0 
5000 - - 89.3 102.0 
* Not analyzed at this concentration. 
Application to Postmortem 
Blood Samples 
Generally, postmortem whole blood is not as 
fluid as antemortem serum or plasma and is 
not easy to work with. Therefore, several sam- 
ples were chosen to demonstrate the potential 
of this method. 
The first blood sample obtained from a de- 
ceased subject showed four benzodiazepines 
(desalkylflurazepam, flurazepam, desmethyl- 
diazepam, and oxazepam) and one antidepres- 
sant (venlafaxine) (Figure 4). The measured 
concentrations were as follows: desalkylflu- 
razepam, 42 ng/mL; flurazepam, 52 ng/mL; 
desmethyldiazepam, 310ng/mL; and ox- 
azepam, 1150 ng/mL. 
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In the second blood sample, also obtained from a deceased 
person, the following substances were clearly identified: ben- 
zodiazepines (dernnoxeparn a d desrnethyldiazeparn), one anti- 
depressant (amitriyptiline), propranolol, and tramadol (Figure 
5). The following concentrations were determined: demoxe- 
pare, 995 ng/rnL; desmethyldiazeparn, 1095 ng/rnL; and ami- 
tryptiline, 605 ng/mL. 
In the third blood sample obtained from a deceased subject, 
two benzodiazepines (lorazeparn and oxazepam) were detected 
(Figure 6), and the following concentrations were measured: 
lorazepam, 905 ng/mL and oxazeparn, 2075 ng/mL. 
Conclusions 
The HPLC procedure described for the simultaneous deter- 
mination of benzodiazepines appears rapid and suitable for 
routine analysis. 
Satisfactory validation data were achieved for linearity, pre- 
cision, and recovery. The LOQ allows measurement of thera- 
peutic concentrations for most benzodiazepines and toxic 
concentrations for flunitrazeparn. For the therapeutic oncen- 
tration of flunitrazepam, the supernatant is evaporated to dry- 
* ij ! -,,,i JEt ............. 
1o 
o, 
nm 
Figure 4. Chromatograms and UV spectra of blood sample obtained 
from a deceased subject. Extraction conditions: injection, 50 pL of 
blood sample (after precipitation), on BioTrap 500 MS extraction (20 x 
4-ram i.d); mobile phase, acetonitrile-phosphate buffer (pH 7.2, 0.3M). 
Analytical conditions: C8 reversed-phase column, Lichrospher Select B 
(125 x 3-ram i.d); mobile phase, acetonitrile/phosphate buffer (pH 2.1, 
0.2M) UV detection at 254 nm 
2dO~ 
50, 
" "~ . . . .  ,~ ,  "~,"  ~,  "~ ' "  ak ' "  "~o ~ "~,  "~ -.~- . . . .  
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Figure 5. Chromatograms and UV spectra of blood sample obtained from 
a deceased subject. Ex raction conditions: injection, 50 pl. of blood 
sample (after precipitation), on BioTrap 500 MS extraction (20 x 4-ram 
i.d); mobile phase, acetonitrile/phosphate buffer (pH 7.2, 0.3M). Ana- 
Igical conditions: C8 reversed-phase column, Lichrospher Select B 
(125 x 3-mm i.d); mobile phase, acetooitrile/phosphate buffer(pH 2.1, 
0.2M); UV detection at 254 nm 
354 
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Figure 6. Chmmatograms and UV spectra of blood sample obtained Nm 
a deceased subject. Extraction conditions: injection, 50 pk of blood 
sample (after precipitation), on BioTrap 500 MS extraction (20 x 4-ram 
i.d); mobile phase, acetonitrile/phosphate buffer (pH 7.2, 0.3M). Ana- 
lytical conditions: cg reversed-phase column, Lichrospher Select a (125 
x 3-ram i.d); mobile phase, acetonitrile/phosphate buffer (pH 2.1,0.2M); 
UV detection at 254 nm 
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ness and dissolved in 100--150 IJL of mobile phase. 
The use of a column-switching technique allows to mini- 
mization of contact with infectious biological fluids like blood 
and plasma. 
Finally, the proposed method is notonly suitable for deter- 
mining benzodiazepine i  whole blood samples, but can also be 
applied to other drugs uch as antidepressants. 
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